Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: March 2009
-
By Donald Zuhn — Another day, another bill. The 111th Congress has been on the job for a little more than ten weeks, but despite this short time span, legislators have already introduced seven bills that could significantly impact the life sciences sector if enacted. Among the bills introduced this year are two concerning…
-
By Donald Zuhn — Yesterday, Rep. Anna Eshoo (D-CA) (at right) provided an alternative to Rep. Henry Waxman's (D-CA) follow-on biologics bill, when she introduced the Pathway for Biosimilars Act (H.R. 1548). Rep. Waxman had introduced his own bill (H.R. 1427; the Promoting Innovation and Access to Life Saving Medicines Act) last week. The…
-
By Donald Zuhn — Back in January, the Manufacturing Alliance on Patent Policy (MAPP) released a report indicating that the apportionment of damages provisions H.R. 1908 — the patent reform bill passed by the House in September 2007 — would have severe economic effects (see "Manufacturing Alliance on Patent Policy: Apportionment of Damages Provision…
-
By Suresh Pillai — Sepracor Settles Xopenex Suit With Barr Last week, Sepracor Inc. and Barr Pharmaceuticals, Inc. (a Teva Pharmaceuticals subsidiary) entered into a settlement agreement that effectively ends a dispute between the two companies over the patent family covering Xopenex®, an inhaled asthma treatment. Sepracor's initial complaint against Barr, filed in July…
-
By Christopher P. Singer — In a pre-OG Notice dated March 13, 2009, the U.S. Patent and Trademark Office addressed some issues relating to the competency of certain foreign patent offices to act as an International Searching Authority (ISA) under the PCT. According to the Notice, the USPTO has found that a number of…
-
By Donald Zuhn — Recently, a number of bills that would significantly impact the biotech and pharma industry have been introduced in Congress. These bills include the Preserve Access to Affordable Generics Act (S. 369), which would prohibit brand name drug companies from compensating generic drug companies for delaying the entry of generic drugs…
-
By Donald Zuhn — The Senate Judiciary Committee has placed the Senate patent reform bill (S. 515) on the agenda for the Committee's March 19th Executive Business Meeting. The meeting, which begins at 10:00 am (Eastern), will be webcast. The meeting agenda and a webcast link can be found at the Committee's website. On…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Sanofi-Aventis U.S. LLC et al. v. Ebewe Pharma Ges.M.B.H. NFG.KG3:09-cv-01116; filed March 11, 2009 in the District Court of New Jersey Infringement…
-
March 23-24, 2009 – 3rd Annual Patent Law Institute (Practising Law Institute) – San Francisco, CA March 24, 2009 – 5th Annual Document Management, E-Discovery, and Litigation Readiness for Life Sciences (American Conference Institute) – New York, NY March 25-27, 2009 – Intellectual Property Counsels' Committee Spring Conference & Meeting (Biotechnology Industry Organization) – Phoenix,…
-
By Christopher P. Singer — In a March 12, 2009 press release, Roche and Genentech announced that the two companies had agreed on terms of a merger agreement. According to the report, the terms of the agreement include Roche's cash acquisition of all outstanding publicly held shares of Genentech stock at $95 per share,…
Patent Docs 